Advertisement

Topics

AACR 2018: Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies

09:54 EDT 16 Apr 2018 | ecancermedicalscience

Just like people, some T cells have excellent memories. These subtypes known as memory T cells may explain why some immunotherapies are more effective than others and potentially lead to researchers designing more effective studies using combination...

Original Article: AACR 2018: Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies

NEXT ARTICLE

More From BioPortfolio on "AACR 2018: Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies"

Advertisement
Quick Search
Advertisement
Advertisement